Literature DB >> 19856729

Nonhemolytic passenger lymphocyte syndrome: donor-derived anti-M in an M+ recipient of a multiorgan transplant.

A T Makuria1, A Langeberg, T M Fishbein, S G Sandler.   

Abstract

Passenger lymphocyte syndrome (PLS) is a well-recognized complication that may follow a hematopoietic progenitor cell or solid-organ transplant. Typically, the syndrome presents as acute hemolysis of the recipient's RBCs, which have become serologically incompatible with blood group antibodies formed by passively transfused donor-origin B lymphocytes. Most cases involve anti-A or anti-B. However, there are cases involving non-ABO serologic incompatibility, as well as cases in which the serologic incompatibility was not associated with clinical evidence of hemolysis. This report describes a case of passenger lymphocyte syndrome in an M+ recipient who developed anti-M after receiving a multiorgan transplant from an M- cadaver donor. Although the temporal events and serologic findings were consistent with a diagnosis of PLS, there was no evidence of in vivo hemolysis associated with the identification of a newly formed anti-M. This report includes a literature review of other case reports of PLS associated with non-ABO antibodies in solid-organ and hematopoietic progenitor cell transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19856729

Source DB:  PubMed          Journal:  Immunohematology        ISSN: 0894-203X


  2 in total

1.  Absence of the spleen and the occurrence of primary red cell alloimmunization in humans.

Authors:  Dorothea Evers; Johanna G van der Bom; Janneke Tijmensen; Masja de Haas; Rutger A Middelburg; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Jaap Jan Zwaginga
Journal:  Haematologica       Date:  2017-04-14       Impact factor: 9.941

Review 2.  Passenger lymphocyte syndrome in liver transplant recipients: a description of 12 cases.

Authors:  Samuel Romero; Pilar Solves; Aima Lancharro; Isabel Cano; Federico Moscardó; Nelly Carpio; Miguel Á Sanz
Journal:  Blood Transfus       Date:  2015-04-28       Impact factor: 3.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.